# PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets?

## TL;DR

This review explores how PDE4 inhibitors like roflumilast and nerandomilast work in different lung diseases, suggesting their effects depend on disease mechanisms rather than drug differences.

## Contribution

The paper proposes that differences in therapeutic outcomes of PDE4 inhibitors are due to disease-specific pathogenesis, not drug-specific effects.

## Key findings

- PDE4 inhibitors show clinical benefits in both obstructive and restrictive lung diseases.
- The drugs affect multiple pulmonary cell types, with only a subset dysregulated in COPD or IPF.
- Observed differences in drug efficacy likely reflect disease pathogenesis rather than drug mechanism differences.

## Abstract

Highly selective inhibitors of the members of the cAMP-selective cyclic nucleotide phosphodiesterases, or PDE4 family, have shown clinically meaningful activity in two different classes of lung disease: roflumilast in obstructive lung disease, specifically chronic obstructive pulmonary disease (COPD), and nerandomilast in restrictive lung diseases characterized by inflammation/fibrosis of the alveolar interstitium, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The beneficial therapeutic benefit of these agents in both of these disorders suggests that they share a common mechanism that underlies their effects on different pulmonary cells and tissues. This review outlines the biochemical, pharmacologic and cellular effects of PDE4-selective inhibitors, emphasizing their role in signal transduction pathways common to many pulmonary cell types. It then compares and contrasts the myriad cellular effects of these agents and their effects in pre-clinical animal models of these disorders. The emerging data are compatible with PDE4-selective inhibitors having targets of action in a large number of pulmonary cell types, only a subset of which is dysregulated in either COPD or IPF. This suggests that differences between the benefits observed with these individual agents in their various clinical indications reflect differences in disease pathogenesis, rather than proven differences in the enzyme-inhibitory effects of the various PDE4 inhibitors that have been studied to date.